Lindus Health (virtual study site)
Boston, Massachusetts, 02111, United States
Location status: Recruiting
NCT Number: NCT06976697
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
Interested in participating?
Request Info22 year–70 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02111, United States
Location status: Recruiting
The study stages include: screening, eligibility evaluation, randomization to active or sham arm (1:1), the first treatment period (weeks 1-10) with sham-control and the optional open-label phase (weeks 11-20) where all treatments will be in active mode.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
In short,
Inclusion criteria
Exclusion criteria
In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.
Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.
Time frame: 10 weeks from treatment initiation.
Mean change in depressive symptoms, measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score, from baseline to week 10. MADRS ranges from 0 to 60, with higher scores indicating more severe depression.
Time frame: 10 weeks from treatment initiation.
Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their MADRS at week 10.
Time frame: 10 weeks from treatment initiation.
Rate of remission remission defined as the percent of subjects with MADRS score ≤ 10 at week 10.
Time frame: 10 weeks from treatment initiation.
Mean change in depressive symptoms, measured by Hamilton Depression Rating Scale (17-items) (HAM-D17), from baseline to week 10. HAM-D17 ranges from 0 to 52, with higher scores indicating more severe depression.
Time frame: 10 weeks from treatment initiation.
Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their HAM-D17 at week 10.
Time frame: 10 weeks from treatment initiation.
Rate of remission defined as the percent of subjects with HAM-D17 score ≤ 7 at week 10.
Time frame: 10 weeks from treatment initiation.
Mean change in depressive symptoms, measured by Patient Health Questionnaire-9 (PHQ-9) total score, from baseline to week 10. PHQ-9 ranges from 0 to 27, with higher scores indicating more severe depression.
Time frame: 10 weeks from treatment initiation.
Rate of response defined as the percent of subjects achieving at least 50% reduction from baseline in their PHQ-9 at week 10.
Time frame: 10 weeks from treatment initiation.
Rate of remission, defined as the percent of subjects with PHQ-9 score ≤ 4 at week 10.
Time frame: 10 weeks from treatment initiation.
The clinical global impression - improvement scale (CGI-I) is a 7-point scale allowing the clinical rater to assess how much the patient's overall condition has improved or worsened since starting the intervention (1. very much improved, 2. much improved, 3. minimally improved, 4. no change, 5. minimally worse, 6. much worse, 7. very much worse).
Sooma Medical Inc
Industry
Safety And Efficacy of Remotely Supervised Home-Based tDCS Treatment Of Major Depressive Disorder
Acronym: REACH-tDCS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07610473
Behavior, Behavioral Symptoms
Phoenix, Arizona, United States
View Trial DetailsNCT07139834
Behavior, Behavioral Symptoms
New York, United States
View Trial DetailsNCT07065240
Anxiety Disorders, Behavior
Chino, California, United States
View Trial DetailsNCT07694076
Behavior, Behavioral Symptoms
Oxford, United Kingdom
View Trial Details